![Frontiers | PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer ... Frontiers | PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer ...](https://www.frontiersin.org/files/Articles/575978/fonc-10-575978-HTML/image_m/fonc-10-575978-g001.jpg)
Frontiers | PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer ...
![EWB Interview, Jean-Louis Thill: Accession process makes Europe more democratic, more peaceful and stronger - European Western Balkans EWB Interview, Jean-Louis Thill: Accession process makes Europe more democratic, more peaceful and stronger - European Western Balkans](https://europeanwesternbalkans.com/wp-content/uploads/2017/04/luxembourg_drapeau.jpg)